Eli Lilly Investor-State Suit
The Canadian government responded to a $500 million suit filed by Eli Lilly & Co. with a blistering attack on the intellectual property practices of the pharmaceutical company.
Accusing Lilly of adopting a “scattershot approach” to applying for patents, Canada’s government presented a detailed rebuttal to claims Lilly made in an investor-state lawsuit. Lilly, it said, tended to file dozens of patent applications for its drugs, claiming new uses for compounds on the basis of little evidence, only to abandon the majority of those applications.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
